Quality control of allergen products with mass spectrometry part I: Positioning within the EU regulatory framework
- PMID: 38425053
- DOI: 10.1111/all.16080
Quality control of allergen products with mass spectrometry part I: Positioning within the EU regulatory framework
Abstract
Mass spectrometry (MS) has advanced greatly and many of its applications are ready for utilization within regulatory procedures and could significantly contribute to overcome challenges in standardization of allergen products. It seems sensible to discuss MS within the regulatory framework, before addressing technical questions. While the application to purified proteins is well established from product development to manufacturer's release analytics, its application to complex products such as allergen products is still under development. It needs to be determined where it can complement or replace established methods or where MS offers limited improvement. Despite its technical appeal and versatility, currently MS is mentioned in regulatory guidelines only as one possible measurement method. For example, no specific MS method is given in the European Pharmacopoeia. We discuss applications of MS within the EU regulatory framework. This includes their advantages and disadvantages and their positioning between research, characterization, manufacturer's release analytics and official batch testing. We discuss the qualitative detection of single and multiple allergens as proof of identity, qualitative to semi-quantitative protein profiles for batch to batch consistency testing, and quantification of allergens to state mass units of allergens. MS may also facilitate standardization of allergen products, reference products and reference standards.
Keywords: allergen mass units; allergen standardization; batch testing; consistence testing; mass spectrometry.
© 2024 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
References
REFERENCES
-
- Shamji MH, Durham SR. Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J Allergy Clin Immunol. 2017;140:1485‐1498.
-
- Bonertz A, Mahler V, Vieths S. Manufacturing and quality assessment of allergenic extracts for immunotherapy: state of the art. Curr Opin Allergy Clin Immunol. 2019;19:640‐645.
-
- Mahler V, Esch RE, Kleine‐Tebbe J, et al. Understanding differences in allergen immunotherapy products and practices in North America and Europe. J Allergy Clin Immunol. 2019;143:813‐828.
-
- Bousquet J, Lockey R, Malling HJ, et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of allergy, asthma and immunology. Ann Allergy Asthma Immunol. 1998;81:401‐405.
-
- Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European academy of allergy and clinical immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131:1288‐1296.e3.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources